Cargando…
Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer
BACKGROUND: Testicular cancer survivors often have impaired gonadal function possibly related to chemotherapy. Platinum is a heavy metal that can be detected at low levels in serum many years after treatment, it is not known whether platinum also persists in semen and if platinum persistence in seme...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817086/ https://www.ncbi.nlm.nih.gov/pubmed/34918879 http://dx.doi.org/10.1002/cam4.4480 |
_version_ | 1784645560541642752 |
---|---|
author | Malone, Eoghan R. Lewin, Jeremy Li, Xuan Zhang, Wen‐Jiang Lau, Susan Jarvi, Keith Hamilton, Robert J. Hansen, Aaron R. Chen, Eric X. Bedard, Philippe L. |
author_facet | Malone, Eoghan R. Lewin, Jeremy Li, Xuan Zhang, Wen‐Jiang Lau, Susan Jarvi, Keith Hamilton, Robert J. Hansen, Aaron R. Chen, Eric X. Bedard, Philippe L. |
author_sort | Malone, Eoghan R. |
collection | PubMed |
description | BACKGROUND: Testicular cancer survivors often have impaired gonadal function possibly related to chemotherapy. Platinum is a heavy metal that can be detected at low levels in serum many years after treatment, it is not known whether platinum also persists in semen and if platinum persistence in semen is associated with impaired fertility. METHODS: Adult cisplatin‐treated testicular cancer survivors were enrolled. High‐Performance Liquid Chromatography‐tandem mass spectrometry was used to measure semen and serum platinum levels. Semen quality and DNA Fragmentation Index (DFI) were assessed. RESULTS: From 11/2017 to 12/2019, 38 patients (median age 32 years; range: 19–52) were enrolled. Median cumulative cisplatin dose was 301 mg/m(2) (range: 274–404). Platinum levels were higher in semen than in blood (p = 0.03). Semen platinum levels were not significantly associated with time from last cisplatin dosing (r = −0.34; p = 0.09) nor cumulative dose (r = −0.10, p = 0.63). Sperm concentration was correlated with time from last cisplatin dosing (r = 0.58, p < 0.001) but not with semen platinum level (r = −0.15, p = 0.46). DFI was not significantly associated with time from last cisplatin dosing (r = 0.55, p = 0.08) or semen platinum level (r = −0.32, p = 0.33). In four patients with serial semen samples, platinum level decreased and sperm concentration and motility increased over time. CONCLUSIONS: Platinum is detected in semen of testicular cancer survivors at higher levels than matched blood samples. These preliminary findings may have important implications for the reproductive health of survivors of advanced testicular cancer, further study is needed to assess the relationship between platinum persistence in semen and recovery of fertility postchemotherapy. |
format | Online Article Text |
id | pubmed-8817086 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88170862022-02-08 Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer Malone, Eoghan R. Lewin, Jeremy Li, Xuan Zhang, Wen‐Jiang Lau, Susan Jarvi, Keith Hamilton, Robert J. Hansen, Aaron R. Chen, Eric X. Bedard, Philippe L. Cancer Med Clinical Cancer Research BACKGROUND: Testicular cancer survivors often have impaired gonadal function possibly related to chemotherapy. Platinum is a heavy metal that can be detected at low levels in serum many years after treatment, it is not known whether platinum also persists in semen and if platinum persistence in semen is associated with impaired fertility. METHODS: Adult cisplatin‐treated testicular cancer survivors were enrolled. High‐Performance Liquid Chromatography‐tandem mass spectrometry was used to measure semen and serum platinum levels. Semen quality and DNA Fragmentation Index (DFI) were assessed. RESULTS: From 11/2017 to 12/2019, 38 patients (median age 32 years; range: 19–52) were enrolled. Median cumulative cisplatin dose was 301 mg/m(2) (range: 274–404). Platinum levels were higher in semen than in blood (p = 0.03). Semen platinum levels were not significantly associated with time from last cisplatin dosing (r = −0.34; p = 0.09) nor cumulative dose (r = −0.10, p = 0.63). Sperm concentration was correlated with time from last cisplatin dosing (r = 0.58, p < 0.001) but not with semen platinum level (r = −0.15, p = 0.46). DFI was not significantly associated with time from last cisplatin dosing (r = 0.55, p = 0.08) or semen platinum level (r = −0.32, p = 0.33). In four patients with serial semen samples, platinum level decreased and sperm concentration and motility increased over time. CONCLUSIONS: Platinum is detected in semen of testicular cancer survivors at higher levels than matched blood samples. These preliminary findings may have important implications for the reproductive health of survivors of advanced testicular cancer, further study is needed to assess the relationship between platinum persistence in semen and recovery of fertility postchemotherapy. John Wiley and Sons Inc. 2021-12-17 /pmc/articles/PMC8817086/ /pubmed/34918879 http://dx.doi.org/10.1002/cam4.4480 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Cancer Research Malone, Eoghan R. Lewin, Jeremy Li, Xuan Zhang, Wen‐Jiang Lau, Susan Jarvi, Keith Hamilton, Robert J. Hansen, Aaron R. Chen, Eric X. Bedard, Philippe L. Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer |
title | Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer |
title_full | Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer |
title_fullStr | Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer |
title_full_unstemmed | Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer |
title_short | Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer |
title_sort | semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer |
topic | Clinical Cancer Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817086/ https://www.ncbi.nlm.nih.gov/pubmed/34918879 http://dx.doi.org/10.1002/cam4.4480 |
work_keys_str_mv | AT maloneeoghanr semenandserumplatinumlevelsincisplatintreatedsurvivorsofgermcellcancer AT lewinjeremy semenandserumplatinumlevelsincisplatintreatedsurvivorsofgermcellcancer AT lixuan semenandserumplatinumlevelsincisplatintreatedsurvivorsofgermcellcancer AT zhangwenjiang semenandserumplatinumlevelsincisplatintreatedsurvivorsofgermcellcancer AT laususan semenandserumplatinumlevelsincisplatintreatedsurvivorsofgermcellcancer AT jarvikeith semenandserumplatinumlevelsincisplatintreatedsurvivorsofgermcellcancer AT hamiltonrobertj semenandserumplatinumlevelsincisplatintreatedsurvivorsofgermcellcancer AT hansenaaronr semenandserumplatinumlevelsincisplatintreatedsurvivorsofgermcellcancer AT chenericx semenandserumplatinumlevelsincisplatintreatedsurvivorsofgermcellcancer AT bedardphilippel semenandserumplatinumlevelsincisplatintreatedsurvivorsofgermcellcancer |